Top Page
Aurora Labs
(Sydney:A3D)
Aurora Labs (A3D) vs. iShares MSCI Australia ETF (EWA)
Aurora Labs Business Overview & Revenue Model
Aurora Labs Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 708.31K | 743.83K | 174.30K | 134.56K | 32.20K | 171.62K |
| Gross Profit | -1.37M | 326.65K | 57.13K | 58.81K | 13.89K | -145.00K |
| EBITDA | -4.77M | -4.54M | -3.23M | -3.37M | -3.70M | -4.81M |
| Net Income | -4.05M | -3.75M | -2.81M | -2.96M | -3.15M | -4.42M |
Balance Sheet | ||||||
| Total Assets | 5.77M | 2.91M | 3.08M | 2.18M | 3.35M | 2.91M |
| Cash, Cash Equivalents and Short-Term Investments | 3.65M | 1.16M | 1.65M | 986.80K | 1.95M | 1.37M |
| Total Debt | 232.00K | 956.01K | 842.94K | 65.39K | 160.53K | 252.00K |
| Total Liabilities | 1.40M | 1.84M | 1.30M | 719.35K | 716.58K | 711.20K |
| Stockholders Equity | 4.37M | 1.07M | 1.78M | 1.46M | 2.63M | 2.20M |
Cash Flow | ||||||
| Free Cash Flow | -4.21M | -2.80M | -2.41M | -2.60M | -2.68M | -1.68M |
| Operating Cash Flow | -3.22M | -2.62M | -2.40M | -2.57M | -2.63M | -1.68M |
| Investing Cash Flow | -988.63K | -180.58K | -7.69K | -23.07K | -48.42K | 6.86K |
| Financing Cash Flow | 5.68M | 2.31M | 3.07M | 1.63M | 3.25M | 1.72M |
Aurora Labs Technical Analysis
Aurora Labs Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$65.82M | 16.67 | 17.38% | 0.49% | -8.28% | 89.71% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
57 Neutral | AU$20.43M | 10.51 | 6.19% | ― | -6.52% | -20.79% | |
55 Neutral | AU$247.67M | -6.90 | -59.01% | ― | 722.02% | -0.77% | |
50 Neutral | AU$30.88M | -6.04 | -264.05% | ― | 327.10% | 1.01% | |
50 Neutral | AU$17.44M | 17.66 | 4.57% | 4.32% | -15.54% | -26.61% | |
41 Neutral | AU$85.64M | -10.58 | -35.18% | ― | 0.88% | 4.88% |
Aurora Labs Corporate Events
Aurora Labs has disclosed a change in director David Trimboli’s interests in the company’s securities, following an on‑market purchase of 255,236 ordinary shares over 5–6 February 2026. The transaction, valued at $13,772.27, adds to Trimboli’s existing direct and indirect holdings, including a substantial package of options exercisable at various strike prices and expiries.
The new shares are held directly by Trimboli, while his pre‑existing share and option interests remain held through Seefeld Investments Pty Ltd as well as in his own name. The disclosure, lodged under ASX listing rules, signals continued insider support for Aurora Labs’ equity and provides investors with updated transparency on a key director’s ownership position.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs reported progress in the December 2025 quarter as it accelerates the commercialisation of its metal additive manufacturing technology and broadens its market exposure beyond development into early-stage deployment. The company formally entered the defence propulsion market through a joint testing and commercialisation agreement with Sovereign Propulsion Systems, securing a maiden $250,000 order for 20 AU4 micro gas turbine propulsion systems that will be tested in bench and flight operations and position Aurora as a recognised supplier to defence. It also deepened its strategic presence in defence and aerospace by signing MOUs with European missile group MBDA and Australian precision armaments manufacturer Ares Armaments, while upgrading its Canning Vale facility with new CNC machinery, expanding industrial 3D-printing revenues including a defence metal-printing order, advancing AS9100D certification, and completing a $5.5 million capital raising and board restructure to underpin near-term growth.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has disclosed a change in director Rebekah Letheby’s interests, with her indirect holdings managed through a jointly held account. Letheby exercised 180,302 options at $0.045 each, converting them into fully paid ordinary shares for a cash consideration of $8,113.59, increasing her total direct shareholding to 540,907 ordinary shares while maintaining 3,000,000 unlisted options exercisable at $0.14 and an unchanged indirect holding of 400,000 shares. The transaction, which did not occur during a closed trading period, marginally boosts director equity alignment with shareholders, signalling confidence in the company’s prospects without altering existing option-based incentive structures.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has disclosed a change in the interests of director David Trimboli, who holds his stake indirectly through Seefeld Investments Pty Ltd. Trimboli exercised 1,916,666 options at $0.045 each, paying a total of $86,249.97, which converted into an equivalent number of fully paid ordinary shares and increased his holding to 6,283,199 shares, while the corresponding options lapsed. The transaction, which did not occur during a closed trading period, signals continued insider commitment to the company’s equity and modestly reshapes the director’s exposure from options to ordinary shares, potentially aligning his interests more closely with those of other shareholders.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has announced the cessation of 37,776,525 options (ASX code A3DAI), which expired unexercised on 22 December 2025. The expiry of this large tranche of options reduces the company’s potential future share dilution, effectively tightening its capital structure and potentially altering the balance of incentives for existing shareholders and option holders as the company progresses with its strategic plans.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs has issued 14,681,487 fully paid ordinary shares following the conversion of an equivalent number of options exercisable at $0.045 and expiring on 22 December 2025, expanding its share capital without undertaking a formal disclosure offering. The company confirmed it has complied with its financial reporting and continuous disclosure obligations under the Corporations Act and stated there is no excluded information, signalling regulatory compliance and transparency as it adjusts its capital structure, a move of interest to existing shareholders and potential investors monitoring dilution and funding pathways.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has applied to list 14,681,487 new fully paid ordinary shares on the Australian Securities Exchange, with the securities to be quoted under the ticker A3D from 23 December 2025. The issuance, arising from the exercise or conversion of existing options or other convertible securities, will expand the company’s quoted share base and may influence its capital structure, liquidity, and market valuation as the additional stock comes onto the market.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited, a publicly listed company known under the ASX code A3D, announced the issuance of unquoted equity securities, specifically consultant options, totaling 4,000,000 units. This move marks a strategic step, utilizing unquoted securities to align employee and consultant incentives effectively, potentially strengthening stakeholder relationships and operational focus.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited announced a change in the director’s interest, with Andrew Garth converting 1,500,000 performance rights into ordinary shares, increasing his total shareholding. This move reflects a strategic alignment of interests and could potentially impact the company’s market perception positively by showcasing confidence in its future performance.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Ltd announced the issuance of 2,333,334 fully paid ordinary shares, resulting from the conversion of options and performance rights. This move is part of their strategic financial operations, potentially impacting their market positioning by increasing the number of shares available to investors.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has announced the issuance of 833,334 fully paid ordinary securities, which are set to be quoted on the Australian Securities Exchange (ASX) under the code A3D. This move signifies an expansion in the company’s capital structure, potentially enhancing its market presence and providing additional resources for growth and development in the competitive 3D printing industry.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has announced the issuance of 1,500,000 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code A3D. This move is part of the company’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its industry positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Ltd has secured a maiden order valued at $250,000 from Sovereign Propulsion Systems for 20 AU4 propulsion systems, marking the start of a multi-phase integration and deployment program. This collaboration aims to enhance propulsion capabilities in the Australian market, particularly for unmanned aerial vehicle manufacturers and Defence Primes. The AU4 systems will be used for field testing, providing real-world data to refine product reliability and support Aurora’s commercialisation strategy. This partnership with SPS is expected to accelerate Aurora’s propulsion development roadmap and strengthen its market position by demonstrating the reliability required for broader commercial and defence market engagement.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Ltd has issued 13,461,539 fully paid ordinary shares as part of Tranche 2 of a placement to sophisticated and professional investors, priced at $0.052 per share. This move is part of a previously announced plan, and the issuance was conducted without disclosure under specific provisions of the Corporations Act, indicating compliance with regulatory requirements and no exclusion of pertinent information.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has announced the quotation of 13,461,539 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code A3D, effective December 3, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s capital structure and market presence, which could have significant implications for its stakeholders and industry positioning.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Ltd has issued a series of unlisted options and performance rights, totaling 19,066,138 securities, with varying exercise prices and expiration dates. This move, conducted without disclosure under specific sections of the Corporations Act, indicates strategic financial maneuvers to potentially enhance the company’s capital structure and stakeholder engagement.
Aurora Labs Limited announced a change in the director’s interest, with David Trimboli acquiring 10 million unlisted options following shareholder approval at the recent AGM. This move reflects strategic financial adjustments within the company, potentially impacting its market positioning by aligning director interests with long-term growth objectives.
Aurora Labs Limited has announced a change in the director’s interest, specifically for Director Andrew Garth. The company has issued 3,000,000 performance rights to Andrew Garth, following shareholder approval at the Annual General Meeting on November 17, 2025. These performance rights are subject to achieving certain milestones and will expire on November 24, 2028. This change reflects the company’s strategy to align the director’s interests with the company’s performance goals, potentially impacting the company’s governance and stakeholder confidence.
Aurora Labs Limited announced the issuance of unquoted securities, including 5 million Unlisted Director Options and 3 million Director Performance Rights, set for issuance on November 24, 2025. This move is part of the company’s strategic initiatives to incentivize its directors, potentially impacting its governance and operational strategies.
Aurora Labs Ltd has issued 32,705,441 fully paid ordinary shares as part of Tranche 2 of its Placement, raising approximately $1.7 million. This move, aimed at sophisticated and professional investors, strengthens the company’s financial position and supports its growth strategy in the 3D printing sector.
Aurora Labs Limited has announced the quotation of 32,705,441 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code A3D, effective November 20, 2025. This move is part of previously disclosed transactions and is expected to strengthen Aurora Labs’ market presence, potentially impacting its operational capabilities and offering new opportunities for stakeholders.
Aurora Labs Limited held its Annual General Meeting on November 17, 2025, where several resolutions were put to vote. Key resolutions included the election of David Trimboli as Director and the approval of a 10% Placement Facility, both of which were carried with significant support. The meeting also saw the ratification of Tranche 1 Placement Shares and the issuance of Tranche 2 Placement Shares and Broker Options, indicating a strategic focus on expanding the company’s financial capabilities.
Aurora Labs Ltd has announced the appointment of Rebekah Letheby as a director effective from November 14, 2025. Letheby holds significant interests in the company’s securities, including 360,605 fully paid ordinary shares and various options, indicating a strong alignment with the company’s future growth. This appointment is likely to influence Aurora Labs’ strategic direction and could impact stakeholder confidence positively.
Aurora Labs Limited has announced the cessation of Ashley Zimpel as a director, effective November 14, 2025. This change in the board may impact the company’s strategic direction and stakeholder relationships, as Zimpel held significant interests in the company, including 167,391 ordinary shares and 1,500,000 unlisted options.
Aurora Labs Limited announced the resignation of Grant Mooney as a director, effective November 14, 2025. The notice details Mooney’s interests in the company’s securities, including ordinary shares and unlisted options, indicating a significant stake in the company. This change in the board may impact the company’s strategic direction and stakeholder interests.
Aurora Labs Limited has announced changes to its board as part of its ongoing renewal initiative. Non-executive directors Ashley Zimpel and Grant Mooney have stepped down, while CEO Rebekah Letheby has joined the board as a director. Letheby, who has been with the company for over eight years, will continue in her role as CEO and work closely with newly appointed Executive Director Andrew Garth to further develop defence partnerships. This strategic move aims to enhance the company’s capabilities in the additive manufacturing sector and support the commercialisation of its defence product suite.